Claire Xu
Jiangsu T-mab BioPharma (China)(CN)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Radiopharmaceutical Chemistry and Applications, HER2/EGFR in Cancer Research, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research
Most-Cited Works
- → Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer(2016)299 cited
- → Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin's Lymphoma: Initial Clinical Results(2021)32 cited
- → Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer.(2021)13 cited
- → A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors(2025)10 cited
- → Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial(2023)6 cited
- → Supplementary Figure 5 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors(2025)
- → Supplementary Table 2 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors(2025)
- → Supplementary Table 6 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors(2025)
- → Supplementary Table 5 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors(2025)